vs
AMERISAFE INC（AMSF）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
AMERISAFE INC的季度营收约是RHYTHM PHARMACEUTICALS, INC.的1.3倍（$80.1M vs $60.1M），AMERISAFE INC净利率更高（10.2% vs -92.6%，领先102.7%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（83.8% vs 10.3%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（43.8% vs 2.8%）
AMERISAFE Inc.是一家专业工伤保险服务商，核心经营市场为美国，覆盖本土49个州，主要为建筑、伐木、货运、制造等高风险行业的中小企业提供定制化工伤险产品及配套风险管理解决方案。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
AMSF vs RYTM — 直观对比
营收规模更大
AMSF
是对方的1.3倍
$60.1M
营收增速更快
RYTM
高出73.5%
10.3%
净利率更高
AMSF
高出102.7%
-92.6%
两年增速更快
RYTM
近两年复合增速
2.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $80.1M | $60.1M |
| 净利润 | $8.1M | $-55.6M |
| 毛利率 | — | 88.1% |
| 营业利润率 | — | -87.1% |
| 净利率 | 10.2% | -92.6% |
| 营收同比 | 10.3% | 83.8% |
| 净利润同比 | -9.0% | — |
| 每股收益（稀释后） | $0.43 | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSFRYTM
| Q1 26 | $80.1M | $60.1M | ||
| Q4 25 | $81.6M | $57.3M | ||
| Q3 25 | $82.0M | $51.3M | ||
| Q2 25 | $81.1M | $48.5M | ||
| Q1 25 | $72.6M | $32.7M | ||
| Q4 24 | $74.0M | $41.8M | ||
| Q3 24 | $78.7M | $33.3M | ||
| Q2 24 | $75.8M | $29.1M |
净利润AMSFRYTM
| Q1 26 | $8.1M | $-55.6M | ||
| Q4 25 | $10.4M | $-47.5M | ||
| Q3 25 | $13.8M | $-52.9M | ||
| Q2 25 | $14.0M | $-46.6M | ||
| Q1 25 | $8.9M | $-49.5M | ||
| Q4 24 | $13.2M | $-43.3M | ||
| Q3 24 | $14.3M | $-43.6M | ||
| Q2 24 | $11.0M | $-32.3M |
毛利率AMSFRYTM
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
营业利润率AMSFRYTM
| Q1 26 | — | -87.1% | ||
| Q4 25 | 15.6% | -82.2% | ||
| Q3 25 | 21.3% | -102.6% | ||
| Q2 25 | 21.5% | -93.4% | ||
| Q1 25 | 15.5% | -143.7% | ||
| Q4 24 | 22.7% | -98.6% | ||
| Q3 24 | 22.6% | -132.0% | ||
| Q2 24 | 18.1% | -139.2% |
净利率AMSFRYTM
| Q1 26 | 10.2% | -92.6% | ||
| Q4 25 | 12.8% | -83.0% | ||
| Q3 25 | 16.9% | -103.1% | ||
| Q2 25 | 17.2% | -96.1% | ||
| Q1 25 | 12.3% | -151.4% | ||
| Q4 24 | 17.8% | -103.6% | ||
| Q3 24 | 18.2% | -131.2% | ||
| Q2 24 | 14.5% | -110.9% |
每股收益（稀释后）AMSFRYTM
| Q1 26 | $0.43 | $-0.83 | ||
| Q4 25 | $0.55 | $-0.73 | ||
| Q3 25 | $0.72 | $-0.82 | ||
| Q2 25 | $0.73 | $-0.75 | ||
| Q1 25 | $0.47 | $-0.81 | ||
| Q4 24 | $0.69 | $-0.71 | ||
| Q3 24 | $0.75 | $-0.73 | ||
| Q2 24 | $0.57 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.2M | $340.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $246.6M | $122.9M |
| 总资产 | — | $442.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMSFRYTM
| Q1 26 | $34.2M | $340.6M | ||
| Q4 25 | $61.9M | $388.9M | ||
| Q3 25 | $54.7M | $416.1M | ||
| Q2 25 | $48.5M | $291.0M | ||
| Q1 25 | $44.8M | $314.5M | ||
| Q4 24 | $44.1M | $320.6M | ||
| Q3 24 | $63.7M | $298.4M | ||
| Q2 24 | $30.6M | $319.1M |
股东权益AMSFRYTM
| Q1 26 | $246.6M | $122.9M | ||
| Q4 25 | $251.6M | $139.1M | ||
| Q3 25 | $274.8M | $148.8M | ||
| Q2 25 | $265.6M | $-11.9M | ||
| Q1 25 | $260.8M | $18.9M | ||
| Q4 24 | $257.3M | $21.7M | ||
| Q3 24 | $314.4M | $11.2M | ||
| Q2 24 | $301.0M | $39.3M |
总资产AMSFRYTM
| Q1 26 | — | $442.3M | ||
| Q4 25 | $1.1B | $480.2M | ||
| Q3 25 | $1.2B | $506.9M | ||
| Q2 25 | $1.2B | $372.7M | ||
| Q1 25 | $1.2B | $386.7M | ||
| Q4 24 | $1.2B | $392.3M | ||
| Q3 24 | $1.3B | $363.6M | ||
| Q2 24 | $1.2B | $381.8M |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
